Immunomedics, Inc.

Ibc Pharmaceuticals, Inc.

Center for Molecular Medicine and Immunology

Stryker Corporation

Other

The Ohio State University

Stryker European Operations Holdings LLC

Immunimedics, Inc.

Stryker European Holdings I LLC

David M Goldenberg

Chien-Hsing Chang

Hans J Hansen

Serengulam V Govindan

Edmund A Rossi

William John McBride

Zhengxing Qu

Sung-Ju Moon

Christopher A D'Souza

Gary L Griffiths

Diane Rossi

David V Gold

Jeng-Dar Yang

Thomas M Cardillo

Jonathan B Gale

Nicholas J Holman

Chien Hsing Chang

Diane Nordstrom

Christine Mazza-Ferreira

Rosalyn D Blumenthal

Donglin Liu

Li Zeng

Rohini Mitra

Nalini Sathyanarayan

Shui-on Leung

Dennis Alan Stratton

Austin J Orand

James G Walen

Eric K Diehl

Beau M Kidman

Vincent Lam

John C Byrd

Bryan Matthew Ulmer

John P Bernero

Eric M Heffernan

Michele J Losman

Chris Chamberlin

David J Veldkamp

Rongxiu Li

Sailaja S Vanama

Bo B Lundberg

Thomas M Behr

Brian James VanDerWoude

Gerard Nunan

Conor Mac An Tuile

David Tallon

Carl Noren

Anastasia Lentine-Jones

David E Modrak

William A Wegener

Sofia Stenler

Alice P Taylor

Britta Wahren

Bruce D Henniges

Richard Franklin Huyser

Jerry A Culp

Steven J Carusillo

Douglas L Tyler

Susanna M Rybak

Natarajan Muthusamy

Chris Philipp

Dianne L Newton

Ivan David Horak

Eva M Horak

Michael K Samoszuk

Robert A Baiocchi

Brian VanderWoude

Walter Lew

Jack D Burton

Paul A Welch

Lapo Alinari

Chein-Hsing Chang

Edward A Rossi

Donald M Malackowski

Zhiliang Ying

Rita Alisauskas

Malik Juweid

Chien-Hsing Ken Chang

William Mcbride

Shui-On Leung

Celeste Aida S Regino

Shui-On 10C University Residence Leung

Hsing Chang Chien

William J Mcbride

Christopher A D'SOUZA

Christopher A D'souza

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.

Antibody-drug conjugates and uses thereof

A personal protection system including a surgical garment that may be mounted to a helmet including an electrically powered assembly, such as a fan. The garment includes a shell adapted for being disposed over the helmet of the personal protection system. The garment also includes a transparent face shield coupled to the shell and an indicia, the indicia being an optically perceivable marking on the garment. The garment may also include a memory, the memory for storing data for regulating the operation of the electrically powered assembly mounted to the helmet. The helmet may also include a sensor for detecting the indicia to selectively allow the actuation of the electrically powered assembly based on the presence or absence of the indicia being positioned adjacent the sensor.

Protective surgical garment including a transparent face shield

A surgical saw system including a saw, a blade cartridge and an attachment. The saw including a housing and a reciprocating shaft. The blade cartridge that may be removably coupled to the saw includes a bar and a rack. The bar includes a first holding feature. The rack is moveably disposed within the bar, and is configured to removably couple to the reciprocating shaft of the saw. The attachment is disposed between and connecting the bar of the blade cartridge to the saw. The attachment may include a coupling feature in selective releasable engagement with the first holding feature of the bar to hold the bar static relative to the saw. The blade cartridge may also include a drive link that extends from reciprocating shaft of the saw and the rack for imparting the reciprocal motion of the reciprocating shaft to the rack.

Surgical saw system including a reciprocating saw blade cartridge

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

A system for cleaning bone that includes a base unit with a motor, a cleaning head with a cleaning element and a mill head with a mill element. Both the cleaning head and the mill head are designed to be coupled to the base unit. Both the cleaning element and mill element have features that facilitate their coupling to the motor. When the cleaning head is attached to the base unit, a motor in the base unit rotates the cleaning element to remove soft tissue from the bone so as to clean the bone. The mill element is placed on the base unit and the cleaned bone placed in the mill head. The actuation of the base unit motor results in the actuations of the mill element. The actuation of the mill element converts the cleaned bone into bone chips.

System for processing bone stock including a bone cleaning head, a bone milling head and base that powers both the cleaning head and the milling head

The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors

A surgical saw blade cartridge includes a bar, a blade and a drive link. The bar includes a first plate and an opposed second plate defining a space therebetween, and an opening in at least one of the plates for releasable connection to a saw. The blade includes a base moveably disposed in the space between the plates and a head integral with the base located outside of the bar. The head has teeth at least as wide as a portion of the bar adjacent the head. The drive link extends through the bar and is moveable therein with a proximal end configured for attachment to a drive component of the saw and a distal end connected to either the base of the blade or a pivot link. The bar includes a structural member adjacent the head that extends forward of the head.

Surgical blade cartridge with a guide bar

A personal protection system including a surgical garment that may be mounted to a helmet including an electrically powered assembly, such as a fan. The garment includes a shell adapted for being disposed over the helmet of the personal protection system. The garment also includes a transparent face shield coupled to the shell and positioned so that, when the garment is disposed over the helmet, the face shield is located in front of the face of the individual. The garment may includes two fastening features spaced apart from one another for releasably securing the shell to the helmet and a conductor that extends between the two fastening features.

The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX. The immunoconjugate may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8 or 10 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.

Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer

A personal protection system () including a helmet () to which a garment () is mounted. The helmet () includes an electrically powered assembly such as a fan (). At least one button () for regulating operation of the electrically powered assembly () is mounted to the face shield () of the garment (). The helmet () includes a detector () that is connected to and monitors the state of the button (). When the button () is depressed, the detector () sends a signal to a controller () that regulates the actuation of the electrically powered assembly. The controller () then sets the operating state of the assembly () so that the assembly () operates in the state desired by the individual wearing the personal protection system () based on the depression of the control button ().

Personal protection system including a hood with a transparent face shield and control buttons on the face shield

The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.

Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.

Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies

A blade cartridge for use with a surgical saw includes a bar and a rack. The bar includes a first holding feature for removably holding the bar static to the saw. The rack includes a base moveably disposed in the bar and has cutting teeth defining extending beyond the bar. A drive link extends from the base, providing a second holding feature for releasably engaging a reciprocating drive integral with the saw. One of the base and the bar includes a guide slot. The other of the base and the bar includes a static member extending into the guide slot. The guide slot and the static member allow the rack to reciprocally move from proximal to distal to proximal along a longitudinal axis of the bar. The bar includes two plates and a spacer between the plates. The base is located between the plates.

Reciprocating saw blade cartridge that includes a static bar to which a reciprocating rack is attached

Growing community of inventors

Mendham, NJ, United States of America

David M Goldenberg